PASG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Passage Bio Inc (PASG) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 to invest. The stock lacks clear positive catalysts, has weak financial performance, and no significant trading signals or trends to support an immediate investment decision. It is better to hold off for now and monitor for stronger indicators.
The technical indicators for PASG are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 35.798, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 6.729), but there is no clear upward momentum.
No significant positive catalysts identified. Analysts maintain a Buy rating, but the price target was significantly lowered from $67 to $23, reflecting tempered expectations.
Weak financial performance with no revenue growth, negative net income (-$12.98M), and declining EPS (-4.08). No recent news or significant insider/hedge fund activity. The stock trend analysis suggests a potential decline in the next week and month.
In Q4 2025, the company reported no revenue growth (0% YoY), a slight improvement in net income (-$12.98M, up 2.03% YoY), and a decline in EPS (-4.08, down -0.73% YoY). Gross margin remains at 0%. Overall, financial performance is weak.
Canaccord analyst Whitney Ijem lowered the price target from $67 to $23 while maintaining a Buy rating. This reflects a cautious outlook despite ongoing enrollment and dosing in the company's lead programs.
